Abstract
The second leading cause of cancer-related death is colon cancer. Combination chemotherapy can lessen the chance of re-occurrence and demise due to recurred or illness that has spread in patients who have had curative surgery. According to the findings of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) and the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trials, combination regimens that include fluoropyrimidine and oxaliplatin are the current standard of care. Targeted medicines for combination adjuvant treatment in the second and third stages of colon cancer are an assuring area, there is no proof to support its use in this situation at this stage. Postoperative therapy has a well-established role in the elderly population, though the most appropriate regimen is still to be established. Improved surgical and radiotherapy techniques may help the patients achieve better results. Further studies should be undertaken in order to determine patient subgroups prone to recurrence, predict response to therapy, and develop better treatment strategies for individuals with colon cancer
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call